WAY-214156

WAY-214156
Identifiers
  • 2,8-Dihydroxy-6H-dibenzo[c,h]chromene-4,12-dicarbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC19H10N2O3
Molar mass314.300 g·mol−1
3D model (JSmol)
  • C1C2=C(C=CC(=C2)O)C3=C(O1)C4=C(C=C(C=C4C#N)O)C(=C3)C#N
  • InChI=1S/C19H10N2O3/c20-7-10-5-17-15-2-1-13(22)4-12(15)9-24-19(17)18-11(8-21)3-14(23)6-16(10)18/h1-6,22-23H,9H2
  • Key:UGZYFAJTTRGNOX-UHFFFAOYSA-N

WAY-214156 is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.[1][2] It is 100-fold selective for the ERβ over the ERα with an IC50 of 4.2 nM (compare to estradiol with IC50 values of ~3–4 nM for both the ERα and ERβ).[1] The drug is less selective for the ERβ than is prinaberel (ERB-041, WAY-202041), another selective ERβ agonist, but is more potent in comparison.[1] WAY-214156 may produce anti-inflammatory effects via the ERβ and has been proposed as a potential treatment for inflammatory conditions such as rheumatoid arthritis.[1][3]

See also

References

  1. ^ a b c d Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC (January 2008). "Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes". Journal of Immunology. 180 (1): 630–636. doi:10.4049/jimmunol.180.1.630. PMID 18097065.
  2. ^ Serock MR, Wells AK, Khalil RA (November 2008). "Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause". Recent Patents on Cardiovascular Drug Discovery. 3 (3): 165–186. doi:10.2174/157489008786263970. PMID 18991792.
  3. ^ Roman-Blas JA, Castañeda S, Cutolo M, Herrero-Beaumont G (November 2010). "Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study". Arthritis Care & Research. 62 (11): 1588–1593. doi:10.1002/acr.20275. PMID 20556817. S2CID 19511497.